What's Happening?
Clinigen, a global pharmaceutical services company, has appointed Greg Skalicky as its new Chief Executive Officer (CEO), effective July 20, 2026. Skalicky succeeds Dr. Varun Sethi, who served as Acting CEO since September 2025. With over 30 years of
experience in the pharmaceutical, biotechnology, and healthcare sectors, Skalicky is expected to lead Clinigen through its next phase of growth. His previous roles include President of Eversana, where he developed an integrated commercialization model, and senior positions at Syneos Health and PharmaNet. Skalicky's appointment is part of Clinigen's strategy to enhance its position as a trusted partner in clinical trial services and global compassionate use programs.
Why It's Important?
The leadership change at Clinigen is significant as the company seeks to expand its global footprint and strengthen its partnerships with pharmaceutical and biotechnology firms. Skalicky's extensive experience in commercialization and patient access positions him well to drive Clinigen's strategic goals. His appointment reflects the company's commitment to innovation and operational excellence, which are crucial for maintaining competitiveness in the pharmaceutical services industry. As Clinigen continues to focus on delivering critical medicines, Skalicky's leadership will be pivotal in navigating the complex landscape of global healthcare and ensuring the company's long-term success.
What's Next?
Under Skalicky's leadership, Clinigen is expected to pursue strategic expansion and innovation initiatives to enhance client value and patient access to medicines. The company will likely focus on strengthening its operational capabilities and exploring new partnerships to support its growth objectives. As the pharmaceutical industry evolves, Clinigen may also invest in technology and process improvements to streamline its services and meet the needs of its global clients. Stakeholders will be watching closely to see how Skalicky's vision and expertise translate into tangible outcomes for the company and its partners.
